Daiichi Sankyo Company, Limited

Kyoto Pharmaceutical Industries, Ltd.

Junya Kawai

Shinji Tanaka

Ken Ishii

Keiji Saito

Osamu Iwamoto

Hitoshi Ohki

Katsuyoshi Nakajima

Hidekazu Inoue

Hiroyuki Tsuruoka

Nobuyuki Ohkawa

Nobuya Kurikawa

Masahiro Ota

Momoko Ogitani

Natsumi Nishihama

Wataru Saitoh

Tsuyoshi Soneda

Masaharu Inui

Masaki Miyazaki

Rieko Takano

Yoshihiro Ogura

Yuma Umezaki

Tomohiro Honda

Masafumi Ofuku

Shunsuke Takashima

Wakana Yokozeki

Masaya Fujii

Masafumi Ando

Teppei Fujimoto

Kazuya Otake

Tadashi Toki

The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1): wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

Benzotriazole compound

An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases, and the present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof,

Urea compound having substituent

Provided is a novel compound or a salt thereof inhibiting MTHFD2 and useful for treating a disease caused by overexpression of MTHFD2, a disease involved in overexpression of MTHFD2 and/or a disease associated with overexpression of MTHFD2. Solution Provided is a sulfonamide derivative having a coumarin skeleton represented by the following formula (I) and having various substituents: wherein R, R, R, R, R, Rand Rare the same as defined in the specification,and a salt thereof.

Sulfonamide derivative having coumarin skeleton

Growing community of inventors

Ota-ku, Japan

Junya Kawai